Search

Displaying results 3861 - 3870 of 8010 in total
  1. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    [L31668] This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal … Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines.

  2. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic … [L41305] As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like

  3. Drug

    Lutetium Lu 177-DTPA-omburtamab

    go.drugbank.com/drugs/DB31015
    Investigational

    Lutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of [omburtamab] conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).[L54566]

  4. Drug

    Gremubamab

    go.drugbank.com/drugs/DB15014
    Investigational

    Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).

  5. Drug

    Reldesemtiv

    go.drugbank.com/drugs/DB15256
    Investigational

    Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).

    Synonyms: CK-2127107
  6. Drug

    Buntanetap

    go.drugbank.com/drugs/DB15317
    Investigational

    Buntanetap (previously known as Posiphen) is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease).

  7. Drug

    Apramycin

    go.drugbank.com/drugs/DB04626
    InvestigationalVet approved

    It is not approved for use in humans.

  8. Drug

    Methysergide

    go.drugbank.com/drugs/DB00247
    ApprovedWithdrawn

    It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids.

    Categories: Heterocyclic Compounds with 4 or More Rings
  9. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).

  10. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.